CIRM Funded Clinical Trials

A phase I/II study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) for the treatment of adults with COVID-19

Disease Area:
CIRM Grant:
Award Value:
Trial Sponsor:
Celularity Inc.
Trial Stage:
Phase 1/2
Trial Status:
Unknown status
Targeted Enrollment:
86 ID:


This trial will use blood stem cells obtained from the placenta to generate natural killer (NK) cells, a type of white blood cell that is a vital part of the immune system, and administer them to patients with COVID-19.  NK cells play an important role in defense against cancer and in fighting off viral infections.  The goal is to administer these cells to locate the active sites of COVID-19 infection and destroy the virus-infected cells. 


Phase I/II Study


Safety, tolerability, and efficacy 

CIRM Clinical Trial Resources

Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox

Video on Stem Cell Trials

Other Resources

ISSCR Patient Website